ADME Toxicology Testing Market Share

ADME Toxicology Testing Market Overview

The ADME Toxicology Testing Market is projected to reach USD 3.02 Billion by 2032 at 12.1% CAGR during the forecast period 2023-2032. The ADME Toxicology Screening System is an integrated workstation that describes the properties of pharmacological molecules in terms of absorption, distribution, metabolism, and excretion. The system is equipped with sample testing software that is highly integrated. It also performs precise toxicity tests for drug research and biopharmaceutical manufacturing. The expanding use of ADME toxicology testing by pharmaceutical and biotechnology companies, as well as growing concerns over the use of animals in clinical trials, have aided the expansion of the toxicology testing industry. The region of Asia-Pacific was predicted to be the fastest-growing region for ADME toxicity testing globally. Increased efforts for the development of new diagnostic equipment and the adoption of modern technologies to improve the standard of diagnostic tests. The market is primarily driven by increased medication research and development and rising demand for various disease treatments. Pharmaceutical businesses have benefited from increasing technology breakthroughs and early identification of toxicology in R&D by reducing drug discovery time, expense, and test complications. Furthermore, rising healthcare awareness and increased government and private sector investments in the healthcare sector are expected to drive market expansion. However, high test prices and strict government norms and regulations related to ADME toxicity testing are key roadblocks to industry expansion. During the forecast period, ongoing R&D in the field of ADME toxicity testing is expected to open up new opportunities.

ADME Toxicology Testing Market Segment Insights:

The ADME Toxicology Testing Market is segmented on the basis of method, technology, application, and end-user. The Market, by method is categorised into cellular assay, biochemical assay, in silica, and ex-vivo. The technology segment is categorised into cell culture, high throughput, molecular imaging, and OMICS technology. On the basis of application, the ADME Toxicology Testing Market is segmented into systemic toxicity, renal toxicity, hepatotoxicity, neurotoxicity, and others. On the basis of end-user, the market is segmented into hospitals and clinics, diagnostic centres, pathological labs, and others.

On the basis of region, the global ADME Toxicology Testing Market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.

Regional Market Summary

It is projected that the Americas dominated the global ADME toxicology testing market owing to the growth in the North America region which is largely attributed to the factors such as increase in research funding, growing awareness on the benefits of ADME toxicology testing for commercial industries, and high adoption of toxicology testing in research. These factors have cumulatively influenced the growth of the market in this regionEurope stood second largest in the ADME toxicology testing market owing to high acceptance of toxicology testing in research. Additionally, development in research expenditure was also responsible for the development of market. Moreover, in January 2014, Cyprotex PLC, a UK based company signed an acquisition agreement with CeeTox, Inc. for its business. The company intended to expand its portfolio for in-vitro toxicity assays and screening services to the Cosmetics and Personal Care Industry.

Asia-Pacific was projected to be the fastest growing region for the global ADME toxicology testing market in 2017. The factors attributed to the due to increased efforts for development of new diagnostic devices and adoption of newer technologies to improve the standard of diagnostics assays being supplied. China and Japan are key countries contributing to market growth.The Middle East and Africa holds the least share in the global ADME toxicology testing market due to the presence of poor health expenditure and economically diverse countries. However, the market is expected to witness growth due to increasing toxicology care programs in the Middle East.

ADME Toxicology Testing Market Segmentation

ADME toxicology testing Method Outlook

•        Cellular Assay


•        Biochemical Assay


•        In Silica


•        Ex-vivo

ADME Toxicology Testing Technology Outlook

•        Cell Culture
  


•        High Throughput


•        Molecular Imaging


•        OMICS Technology

ADME toxicology Testing Application Outlook

•        Systemic Toxicity


•        Renal Toxicity


•        Hepatotoxicity


•        Neurotoxicity


•        Others

ADME Toxicology Testing End-Users Outlook

•       Hospitals and clinics


•       Diagnostic centers


•       Pathological Labs


•       Others

ADME Toxicology Testing Region Outlook

•        Americas


•        Europe


•        Asia-Pacific


•       Middle East & Africa

Global ADME toxicology testing Global Market, by Key Players:

•        Promega Corporation
  


•        Agilent Technologies, Inc.


•        Thermo Fisher Scientific, Inc.
  


•        Bio-Rad Laboratories, Inc.


•        Beckman Coulter, Inc.


•        Cellartis AB


•        Cyprotex PLC.


•        Life Technologies Corporation


•        Optivia Biotechnology, Inc.


•        Accelrys, Inc.


•        Molecular Discovery Ltd.


•        Cyprotex PLC


•        MultiCASE, Inc.

Recent Development

Machine learning operations platform Chief will be launched in July 2021. The first no-code, pay-as-you-go artificial intelligence (AI) platform for drug development has been established by AI in collaboration with the Medicines Discovery Catapult increasing the stake of the ADME Toxicology Testing Market. Mydecine Innovations Group, an emerging biopharma and life sciences company dedicated to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced the launch of its in-silico drug discovery program in collaboration with University of Alberta researchers in June 2021.

Intended Audience:

• Pharmaceutical companies


• Biotechnological institutes


• Diagnostics Laboratories


• Pathological Institutes


• Government and private laboratories


• Research and Development (R&D) companies


• Medical research laboratories


• Market research and consulting service providers

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report